Opus Genetics, Inc.

Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company dedicated to developing gene therapies to restore vision and prevent blindness in patients suffering from inherited retinal diseases (IRDs) and other retinal and refractive disorders. The company's mission is to design therapies that address the underlying genetic causes of severe retinal disorders, aiming to deliver durable vision improvement for patients. Headquartered in Durham, North Carolina, Opus Genetics focuses on advancing treatments for conditions with significant unmet medical needs.

The company's pipeline includes seven adeno-associated virus (AAV)-based gene therapy programs. Lead candidates include OPGx-LCA5 for Leber congenital amaurosis type 5 and OPGx-BEST1 for BEST1-related retinal degeneration, with additional programs targeting genes such as RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a small-molecule therapy, which is approved for pharmacologically induced mydriasis and is being developed for potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery.

Led by CEO George Magrath, Opus Genetics has recently achieved several notable milestones. In April 2026, the company secured a strategic financing agreement with Oberland Capital Management LLC, providing access to up to $155 million in non-dilutive funding to accelerate its pipeline. The company was recognized on Fast Company's World's Most Innovative Companies 2026 list in the Biotech category in March 2026. Additionally, Opus Genetics reported promising early results from its Phase 1/2 trial of OPGx-BEST1 in March 2026, demonstrating vision improvements and a favorable safety profile. The FDA has also accepted a supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for presbyopia, with a PDUFA goal date of October 17, 2026.